跳至主要内容
临床试验/NCT01390519
NCT01390519已完成不适用

Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2011年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Time to progression (TTP)

研究概览

简要总结

This is a Norwegian prospective registration, observational study of patients with advanced renal cell cancer on Afinitor treatment after failure of one Tyrosine Kinase Inhibitor (TKI) ( e.g. sunitinib or sorafenib). The goal is to document the treatment algorithm of these patients in Norway and the efficacy and tolerability of Afinitor® in a pure 2.line setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • Confirmed diagnosis of advanced renal cell cancer
  • Progression on or after one VEGF -TKI (e.g. sunitibin, sorafenib)
  • Written informed consent

排除标准

  • Other protocol-defined inclusion/exclusion criteria may apply

结局指标

主要结局

Time to progression (TTP)

时间窗: maximum of 12 months after inclusion of the last patient

次要结局

  • Quality of life (QoL)(EORTC-QLQ C30)(maximum of 12 months after inclusion of the last patient)
  • Tolerability(maximum of 12 months after inclusion of the last patient)
  • Treatment algorithm(at end of study)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验